Conversion of retinal glia into neurons for cell replacement therapy
Generated by a Claude Opus 4.7 agent (max thinking effort, 1M-context). Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Retinal neurodegeneration; conversion of retinal Muller glia into neurons for cell replacement therapy
Modality
Gene Therapy
Mechanism
AAV-mediated retinal glia reprogramming
Target
—
vc_fundable does not match the rNPV envelope shown below (base case is materially negative). The label reflects the deep-dive comparator framing; the engine output is the authoritative number. Treat as “look closer” — see methodology §10 for the archetype-vs-rNPV reconciliation rule.rNPV Envelope
Low
-$73.5M
costs +25% · peak −25%
Base
-$50.1M
cumulative PoS 6.3%
High
-$26.6M
costs −25% · peak +25%
Costs are calibrated to retinal AAV economics: small ophthalmic Phase 1 cohorts in single-vision-impaired-eye safety designs, mid-size Phase 2 dose-finding with structural OCT and visual function endpoints, and pivotal Phase 3 trials that are smaller than systemic gene-therapy programs because vision endpoints are direct and orphan/ultra-orphan populations cap enrollment. Preclinical PoS is held below the gene-therapy default because the underlying biology (in-vivo glia-to-neuron reprogramming) is younger and less translationally validated than RPE65 or RPGR replacement. Phase 1 PoS reflects Tufts NEWDIGS evidence that ophthalmology gene therapies clear early phases at ~2x the BIO baseline, partially offset by mechanism novelty risk. Phase 2 is the binding constraint: durable functional vision restoration from regenerated neurons must be demonstrated, which is harder than restoring a missing protein.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.75
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.672 — composite-score rank #8 of 10 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#9) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Luxturna (Spark Therapeutics/Roche) — voretigene neparvovec-rzyl
Only FDA-approved AAV retinal gene therapy; defines the regulatory path, subretinal-delivery development burden, and ultra-rare-disease commercial ceiling for any retinal AAV asset.
Criteria 2 and 4: launched AAV ophthalmology comparator with similar subretinal delivery and inherited retinal disease pathway. Real-world commercialisation underperformed early $350-750M Wall Street projections; 2018-2023 cumulative sales near $250M with ~$50M annual run-rate.
EDIT-101 (Editas Medicine) — BRILLIANCE CRISPR program
Cautionary clinical precedent for advanced retinal genetic-medicine programs: subretinal CRISPR delivery was tolerable but only 3 of 14 patients met responder threshold, and Editas paused enrollment in Nov 2022 because the addressable LCA10 IVS26 homozygous population (~300 US patients) could not support standalone economics.
Criteria 1 and 3: same in-vivo retinal genetic-medicine modality and inherited retinal disease orphan path; pause/partner-seek decision is the relevant economic precedent for ultra-narrow retinal subgroups (NCT03872479).
Laru-zova / AGTC-501 (Beacon Therapeutics) — AAV-RPGR for X-linked RP
Most advanced active retinal AAV gene-therapy program (Phase 2/3 VISTA registrational), anchoring late-stage trial cost and timing for an inherited retinal disease with a defined male patient population. Beacon's SKYLINE 24-month data showed 57% high-dose response rate in study eyes.
Criteria 1: same subretinal AAV inherited-retinal-disease path; registrational Phase 2/3 VISTA enrollment completed with 12-month topline expected 2H 2026.
Ixo-vec / ADVM-022 (Adverum Biotechnologies) — AAV.7m8-aflibercept for wet AMD
Provides the intravitreal AAV delivery comparator and the larger-market wet-AMD economic ceiling, plus a serious toxicity precedent (INFINITY DME hypotony) that bounds payer/regulator tolerance for novel retinal AAV mechanisms.
Criteria 1 and 2: same intravitreal AAV ophthalmology platform; LUNA Phase 2 with 76% injection-free rate at 26 weeks bounds the wet-AMD opportunity, while INFINITY hypotony events bound the safety envelope.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $25.0M | 30 mo | 45.0% | [4] [5] |
| Phase I | $70.0M | 24 mo | 65.0% | [1] [2] [5] |
| Phase II | $160.0M | 30 mo | 40.0% | [1] [2] [5] |
| Phase III | $220.0M | 36 mo | 60.0% | [0] [2] [4] [5] |
| NDA/BLA Review | $18.0M | 12 mo | 90.0% | [0] [5] |
Multiplier handling: Eligible multipliers (genetic_validation_2.6x, gene_therapy_1.41x, orphan_1.4x, fast_track_or_rmat, pediatric_voucher) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$350.0M peak · WACC 14.0%
Peak revenue. Modeled below the wet-AMD ceiling and well above Luxturna's ~$90M run-rate. The asset's value depends on indication selection: a late-stage RP launch sits in the $150-300M range based on Luxturna's real-world commercialisation gap; broader penetration into geographic-atrophy-adjacent dry AMD or RGC-loss glaucoma could push toward $500M-$1B but only with successful platform extension that is not yet de-risked. The $350M central case treats this as a single retinal degeneration launch with platform optionality, consistent with Beacon and 4D Molecular Therapeutics retinal AAV positioning rather than a Luxturna-style ultra-orphan plateau.
WACC. Mechanism risk drives the high end of biotech WACC: in-vivo glia-to-neuron reprogramming is a younger biology than gene replacement, the broader astrocyte-to-neuron PTBP1 literature has been challenged by fate-mapping studies, and clinical translation of any reprogramming approach has no human precedent. Offsetting factors (orphan economics, AAV manufacturing maturity, JHU trust signal) keep this VC-fundable rather than partnership-only.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$50.1M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$191.1M
P25
-$89.7M
P50 (median)
-$29.2M
P75
-$15.5M
P95
-$4.3M
Prob ≥ 0
4.6%
Comparable launch curves
Revenue trajectories of named comparators
Luxturna (Spark Therapeutics/Roche) — voretigene neparvovec-rzyl
Launched 2017 · peak $85.5M (estimated)
Evidence register
6 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
Luxturna real-world peak revenue benchmark comparators[0].peak_revenue_usd | Commercial performance of AAV gene therapies: Market review and future implications news | 2025-02-15 | high |
EDIT-101 program pause as ultra-orphan precedent comparators[1].selection_criteria | Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial company_filing | 2022-11-17 | high |
Beacon laru-zova Phase 2/3 VISTA registrational anchor stage_profile.phase_3.cost_usd_m | Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP news | 2025-09-30 | high |
Mechanism risk — in-vivo glia-to-neuron reprogramming literature wacc_suggestion | Critical examination of Ptbp1-mediated glia-to-neuron conversion in the mouse retina peer_review | 2022-06-14 | high |
Hopkins/Blackshaw mechanism basis for the JHU asset comparators[0].rationale | Robust reprogramming of glia into neurons by inhibition of Notch signaling and nuclear factor I (NFI) factors in adult mammalian retina peer_review | 2024-07-12 | high |
Gene-therapy and ophthalmology PoS uplift stage_profile.phase_1.pos | Tufts NEWDIGS — Durable Cell and Gene Therapies Have Substantially Higher Clinical Success Rates peer_review | 2023-10-09 | medium |
Thesis
Why this asset earns its top-10 rank
This invention is an AAV-delivered Muller glia reprogramming platform built on the Hopkins Blackshaw lab's published mechanism: combined inhibition of Notch signaling and NFI transcription factors plus pro-neural drivers can convert mature retinal Muller glia into bipolar, amacrine, RGC-like, and limited photoreceptor neurons. The patent's three-distinct-target language maps directly onto the Rbpj plus Nfia/b/x plus pro-neural axis the lab has published. The top-10 ranking is driven by clinical relevance for inherited retinal degeneration, gene-therapy modality fit, IRA shielding for orphan biologics, and credible whitespace beyond gene-replacement strategies that only work for monogenic protein loss.
Comparator economics frame both the upside and the discipline. Luxturna is the only approved AAV retinal gene therapy and runs near $50M annual sales, well below early Wall Street $350-750M projections, because the addressable RPE65 population is ultra-rare. EDIT-101 shows what happens when the eligible patient pool is too narrow: Editas paused BRILLIANCE in 2022 with only 3 of 14 patients responding and is now seeking a partner. Beacon's laru-zova VISTA Phase 2/3 anchors the late-stage trial cost and timeline for a defined-genotype RP indication. Adverum's ADVM-022/ixo-vec defines the wet-AMD opportunity ceiling and the safety envelope (INFINITY hypotony). The engine result is -$73.5M to -$26.6M, with a base rNPV of -$50.1M and cumulative PoS of 6.3%; the spread reflects the asset's sensitivity to indication selection and to whether reprogramming durability translates into measurable visual function.
The verdict is investable but mechanism-novel. It earns the top-10 slot because the rubric rewards clinical relevance, gene-therapy modality fit, and whitespace beyond gene-replacement, and because the underlying biology is published in Science Advances by Hopkins co-authors rather than the disputed PTBP1 reprogramming literature. The funding-path archetype is vc_fundable for a focused inherited retinal degeneration lead, with platform optionality across glaucoma RGC loss and AMD-adjacent photoreceptor disease only de-risked after first-in-human functional vision data.
Key risks
Asset-specific, not generic biotech risks
- In-vivo retinal reprogramming has no human precedent and the broader astrocyte-to-neuron PTBP1 literature was challenged by independent fate-mapping; the asset must avoid being lumped with disputed claims.
- Bipolar and amacrine outputs are well-documented from Ascl1/Atoh combinations, but functional photoreceptor or RGC restoration sufficient to recover patient vision is not yet established in non-human primates or humans.
- Luxturna's real-world ~$50M annual revenue shows that even an approved AAV retinal therapy can underperform projections; indication selection (RP, AMD subset, glaucoma) will dominate the commercial outcome.
- Beacon (XLRP), 4D Molecular Therapeutics, Ocugen, and Atsena are advancing competing AAV retinal programs; reprogramming must demonstrate efficacy in patients where gene replacement is not applicable to differentiate.